RANKL Inhibition With Denosumab Does Not Influence 3‐Year Progression of Aortic Calcification or Incidence of Adverse Cardiovascular Events in Postmenopausal Women With Osteoporosis and High…

Overview of attention for article published in Journal of Bone & Mineral Research, July 2013

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (69th percentile)
Above-average Attention Score compared to outputs of the same age and source (55th percentile)

Mentioned by

policy: 1 policy source

twitter: 4 X users

Readers on

mendeley: 108 Mendeley

So far, Altmetric has seen 5 X posts from 4 X users, with an upper bound of 10,859 followers.

@KatieKwonMD @JamesNovakNeph Vascular calcification #KidneyWk https://t.co/eNvEwEI5eN

#osteoporosis @ASBMR RANKL inhibition with denosumab does not influence 3-year progression of aortic calcifica... http://t.co/Lhmwb5Dp8e

Newly Accepted #JBMR Article: RANKL Inhibition With Denosumab Does Not Influence 3-year Progression of Aortic...http://t.co/ne77WhGxVm

Newly Accepted #JBMR® Article: RANKL Inhibition With Denosumab Does Not Influence 3-year Progression of Aortic... http://t.co/ne77WhGxVm

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 1 additional X posts.